Skip to main content

Table 1 (abstract P26). Results from final ranking survey. Top 7 priorities from each group, ranked from highest to lowest priorities

From: Proceedings of the 2018 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting

AF Cure JM* LFA*
Genetic/Environmental Etiology New Treatments Genetic/Environmental Etiology
Personalized medicine Flares (triggers, prevention, treatment) Quality of life
Medication side effects Medication side effects Medication side effects
Growth and development Standards to measure disease activity and/or remission Pain management
Flares (triggers, prevention, treatment) Genetic/Environmental Etiology Long-term health/prognosis
New Treatments JM complications ( i.e. rash, calcinosis, lipodystrophy) Fatigue
Pain management Risk of other autoimmune diseases Flares (triggers, prevention, treatment)
  1. *For Cure JM and LFA, cure was the highest ranking priority. Our aim for this study was to identify research priorities other than cure and thus we eliminated these from the final results